Individuals with HIV who are in need of a salvage therapy and who meet certain criteria may be able to access T-20, also known as Fuzeon, through a compassionate use program expected to begin in October.

T-20, a member of a new class of drugs called fusion inhibitors, is administered by injection twice a day. FDA approval of the drug is expected soon.

Only 600 slots in the program are available. Individuals enrolling in the program must be 6 years old or older, have a viral load greater than 10,000 copies and a CD4 count of less than 100 cells/mm³ while on highly active antiretroviral therapy. Individuals must also "be limited by the currently commercial available antiretroviral agents as per the judgment of the investigator," according to a letter announcing the program.

Individuals interested in the program should consult their physicians.